LTX-401 / Lytix - LARVOL DELTA

Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 (Lytix Biopharma Press Release) - "LTX-401: New superior formulation with enhanced anticancer effects and extended patent life; clinical trials planned for 2026."

New trial • Oncology